The Invention relates to the pharmaceutical industry and medicine, in particular, The New Peg interferon conjugated derivatives and the discovery of a New functional, highly Stable interferon to polyethylene glycol with an activity of interferon alfa with reduced immunogenicity. With biological effects proiongados Pharmaco Kinetic parameters and improved General formula.Integral values of N - 227 to 10 000, so that the molecular weight of Peg is around 10000 40000da M - integer4； IFN； natural or recombinant polypeptide having the activity of IFN Alpha.Also, The Invention relates to a drug containing the Conjugate of the formula (1), Pharmaceutical compositions containing Peg IFN conjugate and therapeutically acceptable excipients, ideal for the treatment of Viral Infections and cancer, also associated diseases S with primary or secondary immunodeficiency.The Invention relates to the use of conjugate of formula (1) in medicinal products, which have antiviral, antiproliferative and immunomodulatory approaches, and the treatment of diseases associated with immunodeficiency, primary or secondary conjugate (formula 1) and the container with such Pharmaceutical composition.La invención está relacionada a la industria farmacéutica y medicina, en particular, aI nuevo PEG-interferón derivados y al descubrimiento de un conjugado nuevo funcional, aitamente estable de interferón a polietileno glicol con una actividad de interferón alfa, con inmunogenicidad reducida, con efectos biológicos proiongados y parámetros fármaco-kinéticos mejorados de fórmula general. n- valores integrales de 227 a 10 000, así que eI peso molecular de PEG es de alrededor de 10000 40000Da； m - integer4； IFN natural o recombinante polipéptido teniendo la actividad de IFN-alfa. También, la invención está relacionada a drogas conteniendo el declarado conjugado de la fórmula (1), composiciones farmacéuticas conteniendo PEG-IFN conjugado y terapéuticamente aceptable excipientes ideales para el tratamiento
